活动后气短、上楼乏力、长期疲惫、食欲减退……这些"小毛病"常被简单归结为老了、累了，但也可能 是心力衰竭（简称"心衰"）的重要信号。随着人口老龄化加剧和心血管疾病谱变化，心衰已成为我国公 共卫生的重要挑战。北京医院杨杰孚、王华团队近期在《欧洲心脏杂志》发表的研究预测，到2035年， 我国心衰患者数量将增长至2270万，较2021年增加超七成。 心衰是冠心病、高血压等心血管疾病发展的严重或终末阶段，此时心脏泵血功能衰退，再也无法有力地 将血液输送到全身，进而引起缺氧和瘀血。其典型表现包括呼吸困难、乏力、下肢水肿等，严重时可能 危及生命。 上述研究中，研究者基于2021年全球疾病负担研究、中国心血管健康联盟注册数据库和国家医保数据， 预测了2025~2035年心衰负担及其对经济发展的影响。研究预计，从2021年至2035年，我国心衰患者总 数将由1310万激增至2270万，增幅高达73%，在此期间，年龄标准化患病率从693.5例/10万人攀升至 760.7例/10万人。其中，60岁以上人群患病率增长最快，35~39岁年轻患者比例也有明显上升。 研究还提到，2025~2035年，心衰导致的累计经济损失预计超过1万亿 ...

今天分享的是：2025年中国康养产业趋势报告 报告共计：80页 康养产业迈入9.8万亿新阶段："未老先养"成趋势，智慧融合引领升级 近日发布的《2025年中国康养产业趋势报告》揭示，中国康养产业正以前所未有的速度扩容与深化，预计2025年市场规模将达到9.8万亿元。产业驱动逻辑 已从单一养老需求，扩展为全龄健康管理、政策系统赋能与科技智慧融合的多元动力体系，标志着行业进入规模化、标准化与品质化发展的关键阶段。 报告指出，康养已超越传统养老概念，成为覆盖全生命周期的主动健康实践。其内涵深度融合医疗、养生、旅游、文化、科技等多领域，构建协同生态。当 前产业发展呈现出鲜明特征：顶层设计进入实质落地期，相关示范项目与标准体系加速完善；人工智能、物联网、服务机器人等"硬核科技"从辅助工具升级 为核心生产力，驱动"智慧康养"场景广泛落地；同时，产教融合加速，各地康养产业学院的成立为行业专业化发展储备人才。 市场需求侧正在发生深刻变革。最显著的趋势是"未老先养"，康养参与年龄显著前移。30至50岁的职场人群成为新兴主力军，他们与追求品质生活的"新老 人"共同构成了多元化、分层化的消费市场。超过七成用户认为康养"非常重要"， ...

Core Viewpoint - The article emphasizes the importance of employee health management as a strategic investment for companies, highlighting its role in enhancing productivity and competitiveness while contributing to the broader "Healthy China 2030" initiative [1][2]. Group 1: Importance of Employee Health Management - Employee health is crucial for corporate productivity, with 60% of employees in China reported to be in suboptimal health, leading to an annual absenteeism rate of 8.5% and an average medical expenditure of over 2800 yuan per person [1]. - Investing in employee health management can yield significant returns, with studies indicating that every 1 yuan spent can reduce medical costs by 3.2 yuan and absenteeism losses by 2.7 yuan [2]. - Companies that implement systematic health management see an average productivity increase of 20.3% and a reduction in indirect economic losses by 42% [2]. Group 2: Challenges in Health Management Services - The diversity in employee age, job roles, and health conditions makes it difficult to standardize health management services [3]. - Insurance companies often lack the capability to integrate medical resources effectively, relying on third-party providers, which can lead to inconsistent service quality [3]. - Data interoperability issues between insurance companies, hospitals, and corporate HR systems hinder the effectiveness of health management [3]. Group 3: "Four Arrivals" Service System - The "Four Arrivals" service system by Ping An integrates insurance, medical services, and health management into a closed-loop ecosystem, addressing the shortcomings of fragmented health management services in the industry [4][5]. - The system includes "online consultations," "hospital services," "on-site corporate health services," and "home health services," providing comprehensive support for employees [5][6]. Group 4: Social Value and Long-term Commitment - Ping An prioritizes social value over short-term profits in its health management business, investing heavily in medical resource integration and service development despite low initial profitability [8]. - The company's health management initiatives contribute to public health by alleviating the burden on public healthcare systems and enhancing the overall health of the workforce [8][11]. - By focusing on long-term value creation, Ping An aims to be a benchmark in the industry, supporting the "Healthy China 2030" goals [11].

Core Insights - The year 2025 presents both challenges and opportunities for the Chinese pharmaceutical industry, particularly for Roche China, marking a critical year for structural advancement [1] - Despite a complex external environment, China's improving business climate and supportive innovation policies provide significant opportunities for multinational companies like Roche to deepen their strategic presence in the market [1] Group 1: Company Developments - Roche has invested over 2 billion RMB in Shanghai to establish a new biopharmaceutical production base, marking a milestone in localizing the production of large molecule antibody biologics in China [1] - In the past year, Roche has successfully launched 4 new products or indications in China and included 10 innovative drugs or indications in the national medical insurance directory, enhancing accessibility to innovative therapies for patients [2] - Roche has maintained its position as the fastest-growing among the top five multinational pharmaceutical companies, driven by a strong market performance and a focus on patient needs [2] Group 2: Innovation and Collaboration - Roche has engaged in nearly 10 global exclusive licensing agreements with local innovative pharmaceutical companies, focusing on the development of innovative drugs in oncology and immunology [2] - The company is committed to accelerating the development of China's medical innovation ecosystem, ensuring that more innovative drugs benefit Chinese patients [2] - Roche plans to expand its treatment portfolio in 2026, reinforcing its leadership in oncology and introducing new generation breast cancer drugs, while also advancing in ophthalmology, immunology, nephrology, and neuroscience [3] Group 3: Future Outlook - Roche aims to integrate artificial intelligence and digital technologies across its operations, creating a smart closed-loop system from research and development to patient care [3] - The year 2026 marks Roche's 100th anniversary in China, symbolizing the beginning of a new century of service, with a commitment to making innovative drugs accessible to more patients [3] - The company is dedicated to supporting the "Healthy China 2030" initiative by deepening local collaborations and enhancing its presence in the Chinese market [3]

Core Viewpoint - The establishment of Hainan University Non-Directly Affiliated Sanya Central Hospital marks a new phase of deep cooperation between Hainan University and Sanya Central Hospital, aimed at promoting medical education and research collaboration, supporting the construction of Hainan Free Trade Port, and responding to the "Healthy China 2030" strategy [1] Group 1 - The hospital will leverage Hainan University's strong academic and research resources, particularly focusing on cutting-edge medical fields such as brain-computer interfaces [1] - The initiative includes the advancement of the "850" discipline system and the "101" talent project, aiming to create a new pattern of collaborative development in medicine, education, research, and prevention [1] - The goal is to significantly enhance medical service capabilities in southern Hainan, providing robust health support for the construction of Hainan Free Trade Port and the high-quality development of Sanya [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 BrainAurora Medical Technology Limited 腦動極光醫療科技有限公司 （於開曼群島註冊成立的有限公司） （股份代號：6681） 自願公告 與澳門鏡湖醫院簽署腦健康數字AI技術服務合作協議 本公告乃腦動極光醫療科技有限公司（「本公司」，連同其附屬公司統稱「本集團」） 自願作出，旨在知會本公司股東及潛在投資者本集團於港澳地區之最新業務發展。 本公司董事會（「董事會」）欣然宣佈，本公司之間接全資附屬公司－腦動極光醫學 科技數智（澳門）有限公司（「腦動極光澳門」），已於近期與澳門鏡湖醫院（「鏡湖 醫院」）正式簽署《腦健康數字AI技術服務合作協議》（「該協議」）。雙方將圍繞認 知障礙的數字篩查、評估、訓練及全程健康管理，在澳門地區建立長期戰略合作 關係，共同構建覆蓋「醫院 － 社區 － 家居」的全鏈條腦健康服務新模式（「本次合 作」）。 一、合作背景 董事會認為，本次合作對本集團 ...

Investment Rating - The report does not explicitly provide an investment rating for the industry. Core Insights - The report emphasizes the significant relationship between nutrition and health, highlighting that chronic non-communicable diseases have become a major public health issue in China, with cardiovascular diseases affecting approximately 330 million people [8][10]. - It underscores the importance of nutritional dietary therapy in managing chronic diseases, suggesting that proper nutritional interventions can effectively prevent the onset of these diseases and improve patients' health and quality of life [11][12]. - The report aims to evaluate the effectiveness of nutritional dietary therapy on health indicators, lifestyle habits, and quality of life among chronic disease patients, while also exploring its social significance [34][38]. Summary by Sections Part 1: Background and Overview - Chronic non-communicable diseases are a leading health threat in China, with cardiovascular diseases being the most prevalent [8][10]. - Poor dietary habits are identified as a primary risk factor for chronic diseases, with evidence supporting that nutritional interventions can prevent disease progression and improve health outcomes [11][12]. Part 2: Effect Evaluation Subjects - The study analyzed 152 cases from a clinical database, focusing on demographic characteristics and underlying health conditions of participants [40]. - The majority of participants were female (78.3%) and aged over 55, indicating a focus on middle-aged and older populations [51][54]. Part 3: Improvement and Evaluation of Core Metabolic Indicators - Participants showed significant weight loss and improvements in BMI after nutritional therapy, with an average weight reduction of 7.27 kg and a decrease in BMI of 2.76 [66][68]. - The report indicates that 84.3% of participants achieved a weight loss of over 5%, and 44.6% lost more than 10%, demonstrating the effectiveness of the intervention [69][70]. Part 4: Behavioral, Cognitive, and Quality of Life Changes - The report discusses changes in dietary habits, lifestyle, and overall quality of life among participants, emphasizing the role of nutritional therapy in promoting healthier living [34][36]. Part 5: Summary and Outlook - The report concludes that nutritional dietary therapy is a valuable non-pharmaceutical intervention for chronic disease management, aligning with national health strategies aimed at disease prevention [37][38].

Group 1 - The Boao Forum for Entrepreneurs 2025 opened with the theme "Moving Towards New Directions, Leading the Future" and recognized Changlian Health Management Co., Ltd. as the "2025 Industry Leader" for its diversified, professional, and globalized health management services [1][5] - The forum serves as a significant platform for communication and cooperation among government, business associations, think tanks, and enterprises, having grown into a high-profile industry benchmark over nine years [2][3] - The award selection process was rigorous, focusing on five core dimensions: operational performance, market position, innovation capability, social responsibility, and corporate management, ensuring that each honor is well-deserved [3] Group 2 - Changlian Health's recognition as the "2025 Industry Leader" reflects its comprehensive strength and leadership across the five evaluation dimensions, reinforcing its commitment to health management under the "Healthy China" strategy [5] - The company aims to create a "smart+" health service platform that integrates health management, wellness services, and modern technologies like artificial intelligence, emphasizing innovation and service optimization [5][9] - The health industry is experiencing a golden development period, with the market size projected to reach 9.8 trillion yuan by 2025 and nearly 14.6 trillion yuan by 2030, driven by factors such as population aging and health consumption upgrades [6] Group 3 - Changlian Health's strategy includes diversified layout, professional operation, and global expansion, establishing a comprehensive smart health service ecosystem that covers all scenarios and life cycles [6] - The company integrates high-quality medical resources to provide a one-stop health management service system, including disease prevention, rehabilitation, and personalized health services [7] - Changlian Health collaborates with top hospitals and research institutions, leveraging a team of medical professionals to offer tailored health assessments and follow-up services [7]

Core Viewpoint - In 2025, the professional health insurance market is undergoing a deep adjustment amid slowing industry growth, intensified competition, and upgraded demand. Fosun United Health Insurance is focusing on the "insurance + medical + health management" strategy, achieving breakthroughs in scale and profitability, demonstrating resilience and vitality in high-quality growth, and injecting new momentum into the industry's transformation [1] Group 1: Performance and Financials - In 2025, the company's insurance business revenue reached 7.84 billion, a year-on-year increase of 50%, ranking among the top in growth among professional health insurance companies [2] - The company achieved a net profit of 130 million, marking five consecutive years of profitability, reflecting continuous optimization in operational efficiency and resource integration [2] - By the end of 2025, the company's total asset scale reached 24.1 billion, with net assets of 3 billion, further enhancing its capital strength [2] Group 2: Product Innovation - The company launched the industry's first full lifecycle managed critical illness insurance "Rui Xing Bao" in collaboration with Ruijin Hospital, focusing on "health management in advance" [3] - This product integrates insurance protection with professional medical services, utilizing smart wearable devices and the "Rui Bao Health" app to create a comprehensive health support system covering prevention, diagnosis, and rehabilitation [3] - The innovation shifts insurance services from "post-event compensation" to "proactive management," enhancing the professionalism and credibility of health insurance services through the empowerment of public medical resources [3] Group 3: Capital Strength - In September 2025, the company completed a strategic capital increase of 810 million, raising its registered capital to 1.01085 billion, and successfully introduced international strategic investors such as the International Finance Corporation (IFC) and the Asian Development Bank (ADB) [4] - The diversified shareholder structure brings international risk control concepts, project experience in the health sector, and medical ecosystem resources, further strengthening the synergy of "insurance + medical" [4] - By the fourth quarter of 2025, the company's core solvency adequacy ratio reached 121.05%, and the comprehensive solvency adequacy ratio reached 173.25%, significantly enhancing its capital strength to support business expansion and innovation [4] Group 4: Investment Capability - The company adheres to a long-term value investment philosophy, constructing a portfolio primarily composed of liquid and fixed-income assets, with moderate equity asset allocation [5] - The average investment return rate over the past three years reached 5.08%, and the average comprehensive investment return rate reached 7.09%, placing it at the leading level in the industry [5] - This demonstrates the company's ability to navigate through cycles, providing stable support for profit growth and customer protection [5] Group 5: Ecosystem Collaboration - The achievements in 2025 stem from the company's continuous deepening of the "insurance + medical + health management" ecosystem strategy [6] - The company aims to leverage its capital strength, service capabilities, and ecological layout to actively respond to the "Healthy China 2030" strategy, focusing on inclusive insurance, grassroots health coverage, chronic disease management, and elderly care [6] - The company seeks to contribute to the construction of a national health security system through innovative services and ecosystem collaboration [6]

Core Viewpoint - Insurance funds are significantly penetrating the medical, health, and elderly care industries, with over 400 billion yuan invested, driven by aging population and health strategies [2][4]. Investment Scale and Focus - As of 2025, insurance funds are projected to invest over 1.5 trillion yuan in medical-related assets through various investment products, including debt and equity plans [4]. - Direct investments in the medical and elderly care sectors have reached nearly 30 billion yuan, covering biotechnology, new drug technology, and medical devices [4]. - The insurance industry is also focusing on building elderly care communities, with 130 projects expected by the end of 2024, marking a 38% year-on-year increase [5]. Strategic Shift - Insurance companies are transitioning from "risk compensators" to "health and elderly care ecosystem builders," aiming to create a "second growth curve" through integrated services [2][6]. - The competition is shifting from resource allocation to ecological collaboration efficiency, emphasizing the integration of insurance, services, and data [10]. Market Potential - The health and elderly care industry in China is projected to reach a market size of 9.8 trillion yuan by 2025, with expectations to grow to 14.6 trillion yuan by 2030 [7]. - Policies are encouraging insurance companies to integrate their services with health management and elderly care, enhancing their strategic importance [8]. Future Outlook - The insurance sector is expected to accelerate its investment in health and elderly care, leveraging policy guidance to create differentiated competitive advantages [8][9]. - The focus will be on transforming health management from a cost center to a profit center, with a need for sustainable business models [12]. - Challenges include talent shortages, data integration, and aligning product design with the actual risks faced by the elderly population [12].